Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Brief Summary: Two regimen are currently considered to have highest efficacy for patients with high-risk early stage breast cancer: sequential treatment of high dose epirubicin, taxane, and cyclophosphamide concomitantly with a dual HER2-blockade, and weekly treatment with paclitaxel/non-pegylated liposomal doxorubicin with dual HER2-blockade or carboplatin. The aim of the GeparOcto study is to compare those two regimen/strategies.

Both regimens are myelosuppressive with a significant incidence of chemotherapy induced anaemia.

The second aim of the GeparOcto study is therefore to compare the use of parental ferric carboxymaltose versus physician's choice for the treatment of chemotherapy-induced anemia in patients with iron deficiency.


Options:
A: Arm Label: Carboplatin + background treatment; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: background treatment | Arm Label: background treatment only; Type: ACTIVE_COMPARATOR; Interventions: Drug: background treatment | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin + background treatment | Intervention Type: DRUG; Name: background treatment; Assigned to Arm(s): Carboplatin + background treatment, background treatment only
B: Arm Label: Arm A (observation) (closed to accrual 05/16/2016); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm B (cisplatin or carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Cisplatin | Arm Label: Arm C (capecitabine); Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm C (capecitabine) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm B (cisplatin or carboplatin) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm B (cisplatin or carboplatin)
C: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: PM(Cb); Type: EXPERIMENTAL; Interventions: Drug: non-pegylated liposomal doxorubicin, Drug: Carboplatin, Drug: Paclitaxel, Drug: Pertuzumab, Drug: Trastuzumab, Drug: Ferric carboxymaltose | Arm Label: ETC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Epirubicin, Drug: Cyclophosphamide, Drug: Pertuzumab, Drug: Trastuzumab, Drug: Ferric carboxymaltose | Intervention Type: DRUG; Name: non-pegylated liposomal doxorubicin; Assigned to Arm(s): PM(Cb) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): PM(Cb) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): ETC, PM(Cb) | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): ETC | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): ETC | Intervention Type: DRUG; Name: Pertuzumab; Assigned to Arm(s): ETC, PM(Cb) | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): ETC, PM(Cb) | Intervention Type: DRUG; Name: Ferric carboxymaltose; Assigned to Arm(s): ETC, PM(Cb)

Answer: D